Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

Note from Chairman of BriaCell Therapeutics - October is Breast Cancer Awareness Month

GlobeNewswire October 1, 2019

BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

GlobeNewswire September 25, 2019

BriaCell Announces Private Placement of up to $600,000

GlobeNewswire September 20, 2019

IIROC Trading Resumption - BCT

Canada NewsWire September 19, 2019

BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

GlobeNewswire September 19, 2019

IIROC Trading Halt - BCT

Canada NewsWire September 19, 2019

BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

GlobeNewswire September 16, 2019

Bondarenko Acquires 16.2% Beneficial Ownership of BriaCell Therapeutics Corp.

GlobeNewswire September 10, 2019

BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

GlobeNewswire September 9, 2019

BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

GlobeNewswire August 27, 2019

BriaCell Appoints Richard J. Berman to Board of Directors

GlobeNewswire August 12, 2019

BriaCell Announces $350,000 Equity Investment by Board of Directors

GlobeNewswire July 23, 2019

BriaCell's Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 28, 2019

Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.

GlobeNewswire May 17, 2019

BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

GlobeNewswire May 13, 2019

BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

GlobeNewswire April 23, 2019

BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

GlobeNewswire April 3, 2019

BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

GlobeNewswire April 2, 2019

BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million

GlobeNewswire April 1, 2019

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

GlobeNewswire March 26, 2019